Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

Nature Medicine

Volumn 9, Issue 10, 2003, Pages 1323-1326

  Gattone II, Vincent H ^a   Wang, Xiaofang ^b   Harris, Peter C ^b   Torres, Vicente E ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; MOZAVAPTAN; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MOUSE; NEPHRONOPHTHISIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION;

ANIMALS; AQUAPORIN 2; AQUAPORIN 6; AQUAPORINS; BENZAZEPINES; CYCLIC AMP; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; KIDNEY; MICE; POLYCYSTIC KIDNEY DISEASES; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; TRPP CATION CHANNELS;

ANIMALIA;

EID: 0142073812     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm935     Document Type: Article

References (28)

1. Zerres, K. & Mucher, G. Autosomal recessive polycystic kidney disease. J. Mol. Med. 76, 303-309 (1998).
2. Hildebrandt, F. & Otto, E. Molecular genetics of nephronophthisis and medullary cystic kidney disease. J. Am. Soc. Nephrol. 11, 1753-1761 (2000).
3. Yamaguchi, T. et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 57, 1460-1471 (2000).
4. Hanaoka, K. & Guggino, W. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11, 1179-1187 (2000).
5. Yasuda, G. & Jeffries, W.B. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int. 54, 80-86 (1998).
6. Wallace, D.P., Rome, L.A., Sullivan, L.P. & Grantham, J.J. cAMP-dependent fluid secretion in rat inner medullary collecting ducts. Am. J. Physiol. Renal Physiol. 280, F1019-F1029 (2001).
7. Koulen, P. et al. Polycystin-2 is an intracellular calcium release channel. Nat. Cell Biol. 4, 191-197 (2002).
8. Nauli, S.M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33, 129-137 (2003).
9. Qian, Q. et al. Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells. Hum. Mol. Genet. 12, 1875-1880 (2003).
10. 2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content. Cell Signal. 11, 651-663 (1999).
11. Yamaguchi, T., Nagao, S., Kasahara, M., Takahashi, H. & Grantham, J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am. J. Kidney Dis. 30, 703-709 (1997).
12. Gattone, V.H., Maser, R.L., Tian, C., Rosenberg, J.M. & Branden, M.G. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Develop. Gen. 24, 309-318 (1999).
13. Parnell, S.C. et al. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro. Biochem. Biophys. Res. Commun. 251, 625-631 (1998).
14. Ward, C.J. et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. 30, 259-269 (2002).
15. Olbrich, H. et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat. Genet. 34, 455-459 (2003).
16. 2-receptor-dependent regulation of AQP2 expression in Brattleboro rats. Am. J. Physiol. Renal Physiol. 279, F370-F382 (2000).
17. Ward, C.J. et al. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum. Mol. Genet.; published online 12 August 2003 (doi:10.1093/hmg/ddg274).
18. Cass, L.A. et al. Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol. 19, 5882-5891 (1999).
19. 2+, which causes an ADPKD-like switch in the proliferative response of M-1 cells to cAMP, is associated with increased activation of Src, B-Raf, and ERK, and increased B-Raf protein. J. Am. Soc. Nephrol. 13, 105A (2002).
20. Yamamura, Y. et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105, 787-791 (1992).
21. Wong, L.L. & Verbalis, J.G. Vasopressin V2 receptor antagonists. Cardiovasc. Res. 51, 391-402 (2001).
22. Thibonnier, M., Coles, P., Thibonnier, A. & Shoham, M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 41, 175-202 (2001).
23. Ohnishi, A. et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J. Pharmacol. Exp. Ther. 272, 546-551 (1995).
24. Gabow, P. et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int. 35, 675-680 (1989).
25. Verani, R.R. & Silva, F.G. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. Mod. Pathol. 1, 457-463 (1988).
26. Wu, G. et al. Somatic inactivation of PKD2 results in polycystic kidney disease. Cell 93, 177-188 (1998).
27. Sutters, M. et al. Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells. Kidney Int. 60, 484-494 (2001).
28. Junqueira, L.C.U., Bignolas, G. & Brentani, R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11, 447-455 (1979).